<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742023</url>
  </required_header>
  <id_info>
    <org_study_id>20-0066</org_study_id>
    <nct_id>NCT04742023</nct_id>
  </id_info>
  <brief_title>Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation</brief_title>
  <official_title>Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, randomized, single-blinded controlled trial in which the&#xD;
      investigators evaluate post-operative serum glucose control using conventional point-of-care&#xD;
      glucose monitoring in the morning and before meals (standard of care) versus continuous&#xD;
      glucose monitoring using the Medtronic Guardian™ Sensor 3 continuous glucose monitor. The&#xD;
      investigators will compare the average daily glucose level in the post-operative period&#xD;
      (through post-operative day five) between the two arms in patients with diabetic nephropathy&#xD;
      immediately post-renal transplant. This will serve as a pilot study to in order to power a&#xD;
      main study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 21, 2020</start_date>
  <completion_date type="Anticipated">December 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 21, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Daily Glucose</measure>
    <time_frame>Postoperative day 1 - 5</time_frame>
    <description>The primary outcome of this study is average daily glucose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Hyperglycemic Episodes</measure>
    <time_frame>Postoperative days 1-5</time_frame>
    <description>The number of episodes where glucose goes from &lt;180mg/dl to ≥ 180 mg/dl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycemic Episodes</measure>
    <time_frame>Postoperative days 1-5</time_frame>
    <description>The number of episodes where glucose levels go from &gt; 80 mg/dl to ≤ 80 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Insulin Use</measure>
    <time_frame>Postoperative days 1-5</time_frame>
    <description>The total number of insulin units used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitor Application</intervention_name>
    <description>The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied and values interpreted by nursing.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Finger Stick Glucose Measurement</intervention_name>
    <description>Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin will be administered.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitor Placebo Applied</intervention_name>
    <description>The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied however values will not be interpreted.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 18 years or older&#xD;
&#xD;
          4. Undergoing first-time renal transplantation&#xD;
&#xD;
          5. Have a pre-existing diagnosis of Type 2 diabetes mellitus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age less than 18 years&#xD;
&#xD;
          2. History of prior renal transplant&#xD;
&#xD;
          3. Use of continuous glucose monitoring or insulin pump at time of transplant&#xD;
&#xD;
          4. Insulin infusion requirement during hospitalization&#xD;
&#xD;
          5. Pregnancy or lactation&#xD;
&#xD;
          6. Known allergic reaction to Guardian™ Sensor 3 or adhesives&#xD;
&#xD;
          7. Use of peritoneal dialysis&#xD;
&#xD;
          8. Diagnosis of Type 1 diabetes mellitus&#xD;
&#xD;
          9. History of hypoglycemia unawareness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

